PORTAGE BIOTECH INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.26 USD | +8.24% |
|
-12.52% | -85.71% |
| Apr. 15 | Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives | CI |
| Apr. 12 | Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives | CI |
Valuation
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 87.68 | 53.78 | 5.144 | - | - |
| Enterprise Value (EV) 1 | 87.68 | 53.78 | 5.144 | 5.144 | 5.144 |
| P/E ratio | -5.09 x | -0.48 x | -0.1 x | -0.4 x | -0.5 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 13,345 | 17,404 | 19,784 | - | - |
| Reference price 2 | 6.570 | 3.090 | 0.2600 | 0.2600 | 0.2600 |
| Announcement Date | 8/1/22 | 7/31/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - |
| EBITDA | - | - | - | - | - |
| EBIT 1 | -15.59 | -16.58 | -19.35 | -16.42 | -18.42 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -14.82 | -122.5 | -62.39 | -16.22 | -18.22 |
| Net income 1 | -16.87 | -104.6 | -51.84 | -16.22 | -18.22 |
| Net margin | - | - | - | - | - |
| EPS 2 | -1.290 | -6.490 | -2.720 | -0.6500 | -0.5200 |
| Free Cash Flow | - | - | - | - | - |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 8/1/22 | 7/31/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -3.33 | -4.169 | -4.496 | -4.087 | -3.653 | -4.759 | -4.076 | -4.997 | -5.93 | -4.025 | -4.4 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -3.38 | -4.089 | -4.046 | -4.177 | -3.638 | -5.302 | -109.4 | -6.071 | -6.072 | -48.88 | -4.35 |
| Net income 1 | -2.975 | -3.512 | -7.317 | -1.729 | -0.949 | -7.485 | -94.45 | -5.919 | -5.158 | -39.37 | -4.35 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.2200 | -0.2600 | -0.5500 | -0.1300 | -0.0600 | -0.4400 | -6.000 | -0.3300 | -0.2900 | -1.880 | -0.2200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/23/21 | 2/24/22 | 8/1/22 | 8/29/22 | 11/29/22 | 3/1/23 | 7/31/23 | 8/29/23 | 11/28/23 | 2/28/24 | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 8/1/22 | 7/31/23 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.26
USD
Average target price
7
USD
Spread / Average Target
+2,592.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -85.71% | 5.14M | |
| +1.77% | 42.86B | |
| +45.77% | 41.36B | |
| +12.24% | 42.74B | |
| -8.83% | 27.68B | |
| +7.44% | 25.15B | |
| -23.01% | 18.63B | |
| +30.56% | 12.37B | |
| -1.82% | 11.92B | |
| +8.35% | 11.21B |
- Stock Market
- Equities
- PRTG Stock
- Financials Portage Biotech Inc.
